The UK government recently announced a partnership with German company BioNTech to test vaccines once morest cancer and other chronic diseases.
The project will build on the mRNA technology developed by BioNTech, which provided protection once morest serious diseases caused by the coronavirus. Within the framework of the study, which will begin this fall, it is expected that 10,000 British citizens will receive personalized therapy by 2030.
Until now, cancer has been treated with surgery, radiation therapy and chemotherapy, but in the last decade new treatments have appeared, such as immunotherapy. Our immune system already knows how to fight cancer, but thanks to the latest results, there is a chance that cancer can be cured, or not just a chronic disease to live with.
In December 2022, Moderna and the pharmaceutical company Merck reported positive results regarding the effectiveness of a cancer vaccine. The patients participating in the study were diagnosed with stage III melanoma, where the tumors had already reached the lymph nodes and the tissues located near them. The usual procedure in this case would be to remove the tumor and the surrounding lymph nodes, but using mRNA technology, a personalized vaccine was now created that used the resistance of the immune system to protect the patients. According to the results of the study, the cancer vaccine reduced the risk of recurrence of the disease by 44% compared to the standard approach. Apart from the side effects of the immunotherapy, there were no other unwanted symptoms.
While the findings might potentially change the way medicine views melanoma, the technology may not yet be effective once morest other cancers. In any case, BioNTech is a research center will create in Cambridge, where they will further investigate the reliability of the approach in question.
Our other interesting articles:
https://www.youtube.com/watch?v=videoseries
